Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00345410 · ClinicalTrials.gov registry record · Phase 2
Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 345
- Enrollment target
NCT00345410 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 345 participants.
The verdict
NCT00345410, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 345 participants
- Enrollment target
Study Summary
Primary objective: to assess the effect of AVE1625 on weight loss over a period of 24 weeks in abdominally obese patients with atherogenic dyslipidemia. Secondary objectives: - To assess the dose effect relationship of AVE1625 on HDL-cholesterol and triglycerides plasma levels over a period of 24 weeks - To assess the efficacy of AVE1625 on secondary parameters such as waist circumference and other metabolic parameters over a period of 24 weeks - To assess the safety and tolerabillity of AVE1625 over a period of 24 weeks.
Interventions
- DRUG AVE1625 B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00345410
The ClinicalTrials.gov registry entry for NCT00345410 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVE1625 B is the first listed.
NCT00345410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00345410 about?
NCT00345410 is a clinical study titled "Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia". Primary objective: to assess the effect of AVE1625 on weight loss over a period of 24 weeks in abdominally obese patients with atherogenic dyslipidemia. Secondary objectives: - To assess the dose effect relationship of AVE1625 on HDL-cholesterol and triglycerides plasma levels over a period of 24 we...
What is the current status of trial NCT00345410?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 345 participants. The study started on 2006-06. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00345410?
The interventions under investigation include: AVE1625 B (DRUG).
Who is sponsoring clinical trial NCT00345410?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.